IPA seeks CDSCO route to regularise legacy drugs lacking central approval records
The Indian Pharmaceutical Alliance has urged the CDSCO to regularise off-patent medicines that have been sold for 15–20 years but lack central approval records, including select anticonvulsant and mood-stabiliser formulations.
What happened
The Indian Pharmaceutical Alliance seeks CDSCO regularisation of legacy off-patent drugs marketed for years without central approval records, including several
Key facts
- 300 mg
- 500 mg
- 100 mg
- 200 mg
- 400 mg
- 450 mg
- 15-20 years
Why this matters
Strategic buyers should diligence central-approval records across legacy portfolios, as a formal regularisation route may improve asset defensibility but expose gaps in acquired anticonvulsant and mood-stabiliser lines.
What to watch
- CDSCO consultation paper, circular or formal pathway defining eligibility for legacy-drug regularisation.
- Requests for bioequivalence, stability, pharmacovigilance or fresh clinical data beyond historical marketing evidence.
- State drug-controller actions against products lacking central approval records.
- Manufacturer notices of SKU discontinuation, temporary supply interruption or revised product licences.
- Pharmacy-level increases in prescriptions being switched to alternate brands, salts or dosage forms.
- Court challenges or patient-group interventions citing continuity of care for established therapies.
- Map exposure to legacy formulations with incomplete central-approval documentation, prioritising chronic-care products and high-volume pharmacy lines.
- Prepare harmonised dossiers covering manufacturing history, bioequivalence where applicable, pharmacovigilance records and current quality standards.
- Build retailer and distributor contingency plans for therapeutic substitution, especially for anticonvulsant, mood-stabiliser and other uninterrupted-treatment medicines.
- Track whether large manufacturers seek collective representation through IPA or file individual regularisation applications.
- Review inventory positions for vulnerable SKUs; avoid excess stock if withdrawal or relabelling requirements appear likely.